Bilateral Panuveitis After Endometrial Cancer Treatment with Dostarlimab: A Case Report
Immune checkpoint inhibitors are used in the treatment of various types of cancer, with their efficacy demonstrated in different clinical trials. However, they are also associated with a range of adverse reactions. To date, no ocular adverse reactions related to the use of Dostarlimab have been published. A case of bilateral panuveitis potentially induced by Dostarlimab is described.
Authors
- Pedro Arriola‐Villalobos (ORCID: https://orcid.org/0000-0002-3573-0842)
- Jacobo Emilio Enríquez-Fuentes (ORCID: https://orcid.org/0000-0001-8816-6360)
- J Lorenzo-Castro
- Ana María Colino-Gallardo
- Marco Antonio Pascual-Santiago
Institutions
- Hospital Clínico San Carlos (ES)
Publication Details
- Journal
- Ocular Immunology and Inflammation
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1080/09273948.2024.2404515
- Citations
- 2
- Primary Topic
- Bartonella species infections research
- Type
- article
- Field-Weighted Citation Impact
- 1.03